Current Concepts on Antiplatelet Therapy: Focus on the Novel Thienopyridine and Non-Thienopyridine Agents
Thienopyridines are a class of drug targeting the platelet adenosine diphosphate (ADP) 2 receptor. They significantly reduce platelet activity and are therefore clinically beneficial in settings where platelet activation is a key pathophysiological feature, particularly myocardial infarction. Ticlo...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2010-01-01
|
| Series: | Advances in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2010/595934 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832560809559982080 |
|---|---|
| author | L. Testa G. G. L. Biondi Zoccai M. Valgimigli R. A. Latini S. Pizzocri S. Lanotte M. L. Laudisa N. Brambilla M. R. Ward G. A. Figtree F. Bedogni R. Bhindi |
| author_facet | L. Testa G. G. L. Biondi Zoccai M. Valgimigli R. A. Latini S. Pizzocri S. Lanotte M. L. Laudisa N. Brambilla M. R. Ward G. A. Figtree F. Bedogni R. Bhindi |
| author_sort | L. Testa |
| collection | DOAJ |
| description | Thienopyridines are a class of drug targeting the platelet adenosine diphosphate (ADP) 2 receptor. They significantly reduce platelet activity and are therefore clinically beneficial in settings where platelet activation is a key pathophysiological feature, particularly myocardial infarction. Ticlopidine, the first of the class introduced to clinical practice, was soon challenged and almost completely replaced by clopidogrel for its better tolerability. More recently, prasugrel and ticagrelor have been shown to provide a more powerful antiplatelet action compared to clopidogrel but at a cost of higher risk of bleeding complications. Cangrelor, a molecule very similar to ticagrelor, is currently being evaluated against clopidogrel. Considering the key balance of ischemic protection and bleeding risk, this paper discusses the background to the development of prasugrel, ticagrelor, and cangrelor and aims to characterise their risk-benefit profile and possible implementation in daily practice. |
| format | Article |
| id | doaj-art-5cebc8f5c48f4f8aadb41782121aeb85 |
| institution | Kabale University |
| issn | 1687-9104 1687-9112 |
| language | English |
| publishDate | 2010-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Hematology |
| spelling | doaj-art-5cebc8f5c48f4f8aadb41782121aeb852025-02-03T01:26:36ZengWileyAdvances in Hematology1687-91041687-91122010-01-01201010.1155/2010/595934595934Current Concepts on Antiplatelet Therapy: Focus on the Novel Thienopyridine and Non-Thienopyridine AgentsL. Testa0G. G. L. Biondi Zoccai1M. Valgimigli2R. A. Latini3S. Pizzocri4S. Lanotte5M. L. Laudisa6N. Brambilla7M. R. Ward8G. A. Figtree9F. Bedogni10R. Bhindi11Interventional Cardiology Department, St. Ambrogio Clinical Institute, 20149, Milan, ItalyInstitute of Cardiology, Ospedale “Le Molinette”, University of Turin, 10124, Turin, ItalyDepartment of Cardiology, Arcispedale S. Anna, University of Ferrara, 44100, Ferrara, ItalyInterventional Cardiology Department, St. Ambrogio Clinical Institute, 20149, Milan, ItalyInterventional Cardiology Department, St. Ambrogio Clinical Institute, 20149, Milan, ItalyInterventional Cardiology Department, St. Ambrogio Clinical Institute, 20149, Milan, ItalyInterventional Cardiology Department, St. Ambrogio Clinical Institute, 20149, Milan, ItalyInterventional Cardiology Department, St. Ambrogio Clinical Institute, 20149, Milan, ItalyDepartment of Cardiology, Royal North Shore Hospital, North Shore Heart Research Group, Kolling Institute, University of Sydney, Sydney NSW 2065, AustraliaDepartment of Cardiology, Royal North Shore Hospital, North Shore Heart Research Group, Kolling Institute, University of Sydney, Sydney NSW 2065, AustraliaInterventional Cardiology Department, St. Ambrogio Clinical Institute, 20149, Milan, ItalyDepartment of Cardiology, Royal North Shore Hospital, North Shore Heart Research Group, Kolling Institute, University of Sydney, Sydney NSW 2065, AustraliaThienopyridines are a class of drug targeting the platelet adenosine diphosphate (ADP) 2 receptor. They significantly reduce platelet activity and are therefore clinically beneficial in settings where platelet activation is a key pathophysiological feature, particularly myocardial infarction. Ticlopidine, the first of the class introduced to clinical practice, was soon challenged and almost completely replaced by clopidogrel for its better tolerability. More recently, prasugrel and ticagrelor have been shown to provide a more powerful antiplatelet action compared to clopidogrel but at a cost of higher risk of bleeding complications. Cangrelor, a molecule very similar to ticagrelor, is currently being evaluated against clopidogrel. Considering the key balance of ischemic protection and bleeding risk, this paper discusses the background to the development of prasugrel, ticagrelor, and cangrelor and aims to characterise their risk-benefit profile and possible implementation in daily practice.http://dx.doi.org/10.1155/2010/595934 |
| spellingShingle | L. Testa G. G. L. Biondi Zoccai M. Valgimigli R. A. Latini S. Pizzocri S. Lanotte M. L. Laudisa N. Brambilla M. R. Ward G. A. Figtree F. Bedogni R. Bhindi Current Concepts on Antiplatelet Therapy: Focus on the Novel Thienopyridine and Non-Thienopyridine Agents Advances in Hematology |
| title | Current Concepts on Antiplatelet Therapy: Focus on the Novel Thienopyridine and Non-Thienopyridine Agents |
| title_full | Current Concepts on Antiplatelet Therapy: Focus on the Novel Thienopyridine and Non-Thienopyridine Agents |
| title_fullStr | Current Concepts on Antiplatelet Therapy: Focus on the Novel Thienopyridine and Non-Thienopyridine Agents |
| title_full_unstemmed | Current Concepts on Antiplatelet Therapy: Focus on the Novel Thienopyridine and Non-Thienopyridine Agents |
| title_short | Current Concepts on Antiplatelet Therapy: Focus on the Novel Thienopyridine and Non-Thienopyridine Agents |
| title_sort | current concepts on antiplatelet therapy focus on the novel thienopyridine and non thienopyridine agents |
| url | http://dx.doi.org/10.1155/2010/595934 |
| work_keys_str_mv | AT ltesta currentconceptsonantiplatelettherapyfocusonthenovelthienopyridineandnonthienopyridineagents AT gglbiondizoccai currentconceptsonantiplatelettherapyfocusonthenovelthienopyridineandnonthienopyridineagents AT mvalgimigli currentconceptsonantiplatelettherapyfocusonthenovelthienopyridineandnonthienopyridineagents AT ralatini currentconceptsonantiplatelettherapyfocusonthenovelthienopyridineandnonthienopyridineagents AT spizzocri currentconceptsonantiplatelettherapyfocusonthenovelthienopyridineandnonthienopyridineagents AT slanotte currentconceptsonantiplatelettherapyfocusonthenovelthienopyridineandnonthienopyridineagents AT mllaudisa currentconceptsonantiplatelettherapyfocusonthenovelthienopyridineandnonthienopyridineagents AT nbrambilla currentconceptsonantiplatelettherapyfocusonthenovelthienopyridineandnonthienopyridineagents AT mrward currentconceptsonantiplatelettherapyfocusonthenovelthienopyridineandnonthienopyridineagents AT gafigtree currentconceptsonantiplatelettherapyfocusonthenovelthienopyridineandnonthienopyridineagents AT fbedogni currentconceptsonantiplatelettherapyfocusonthenovelthienopyridineandnonthienopyridineagents AT rbhindi currentconceptsonantiplatelettherapyfocusonthenovelthienopyridineandnonthienopyridineagents |